| 刘 婕,方 亮,邸东华,王 达,杨 丽.治疗帕金森病精神症状新药匹莫范色林[J].,2018,(1):186-189 |
| 治疗帕金森病精神症状新药匹莫范色林 |
| A New Agent for the Treatment of Parkinson Disease Psychosis: Pimavanserin |
| 投稿时间：2017-02-27 修订日期：2017-03-23 |
| DOI：10.13241/j.cnki.pmb.2018.01.040 |
| 中文关键词: 匹莫范色林 帕金森病 精神病 治疗结果 安全 |
| 英文关键词: Pimavanserin Parkinson disease Psychotic disorders Treatment outcome Safety |
| 基金项目:辽宁省博士科研启动基金项目（201501023） |
|
| 摘要点击次数: 658 |
| 全文下载次数: 409 |
| 中文摘要: |
| 摘要：匹莫范色林(Pimavanserin)是一种新型的选择性5-羟色胺2A（5-HT2A）受体反向激动剂，用于治疗帕金森病患者伴发的错觉、幻觉、妄想等精神症状。临床试验研究表明，其疗效和安全性较现有药物具有明显优势，已于2016年4月29日被美国食品和药物管理局批准上市。本文将从匹莫范色林的药效、安全性、耐受性等方面进行综述，并对该药物的未来发展应用做了展望。 |
| 英文摘要: |
| ABSTRACT: Pimavanserin is a highly selective serotonin 2A receptor inverse agonist, developed to address the symptoms of parkinson disease psychosis (PDP), characterized by visual hallucinations, delusions and illusions. Clinical trials in Parkinson disease patients showed that pimavanserin can significantly reduce psychotic symptoms with no other tolerability or safety concerns. As a result, pimavanserin has been approved on market by the US Food and Drug Administration on April 29th, 2016. This article summarized the efficacy, safety and tolerability of pimavanserin, and carried on the future development prospect. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
